Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of LVRNA012 (Omicron BA.5) mRNA Vaccine in Chinese Adults
NCT05550142Unknown
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Randomised trial of LVRNA012 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by AIM Vaccine Co., Ltd. Primary endpoints: Incidence of solicited adverse events at 28 days, Incidence of unsolicited adverse events at 28 days and 1 more. Status: unknown.
02
Drugs
LVRNA012
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05550142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05550142.